低剂量丁丙诺啡延长氯胺酮抗自杀意念效果:随机双盲安慰剂对照试验
该随机双盲安慰剂对照试验在美国单一门诊中心纳入50例重性抑郁障碍且SSI总分≥6的成人,在单次开放标签静脉氯胺酮(0.5 mg/kg)输注48小时后,按1:1随机接受舌下丁丙诺啡(0.2–0.8 mg/day)或安慰剂4周。丁丙诺啡组SSI总分平均下降11.6(SD=5.8,N=23),安慰剂组下降6.3(SD=7,N=22),Glass delta=0.76(95%CI=0.11,1.39),组间抑郁评分无显著差异,未发生严重治疗相关不良事件。
要点
- 氯胺酮后加用低剂量丁丙诺啡可显著增强并维持抗自杀意念效果。
- 丁丙诺啡组SSI降幅大于安慰剂组,Glass delta=0.76(95%CI=0.11,1.39)。
- 两组抑郁评分无显著差异,未报告严重治疗相关不良事件。
核心结论
- 该随机对照试验首次提供证据表明丁丙诺啡可显著维持并增强氯胺酮在重性抑郁障碍中的抗自杀效果。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在美国单一门诊中心开展。
- 纳入重性抑郁障碍且SSI总分≥6的成人,共50例接受氯胺酮,其中45例完成至少1周后续治疗。
- 单次开放标签静脉氯胺酮(0.5 mg/kg,40分钟输注)48小时后,按1:1随机接受舌下丁丙诺啡(0.2–0.8 mg/day)或匹配安慰剂4周。
主要发现
- 丁丙诺啡组SSI总分平均变化为-11.6(SD=5.8,N=23),安慰剂组为-6.3(SD=7,N=22)。
- Glass delta=0.76(95%CI=0.11,1.39),混合效应模型显示时间×治疗交互作用显著(p<0.001)。
- 两组抑郁评分无显著差异,未发生严重治疗相关不良事件。
关键数值与推荐
- 主要结局为SSI总分从第1天至第31天每周评估的变化。
- 丁丙诺啡剂量范围为0.2–0.8 mg/day,舌下给药,持续4周。
- 氯胺酮为单次开放标签静脉输注0.5 mg/kg,输注时间40分钟。
临床怎么用
- 对于重性抑郁障碍伴自杀意念且SSI总分≥6的成人,可在单次静脉氯胺酮后考虑加用低剂量舌下丁丙诺啡以延长抗自杀效果。
- 丁丙诺啡作为氯胺酮后续治疗可能提供可扩展且安全的治疗选择,但需结合临床评估个体化使用。
局限性
- 研究在单一门诊中心开展,样本量较小(完成至少1周后续治疗者45例)。
- 原文未报告随访时间超过31天的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on treatment to prolong the effects of intravenous ketamine. METHODS: This was a randomized, double-blind, placebo-controlled trial conducted at a single outpatient center in the United States. Adults with MDD and a total score ≥6 on the Scale for Suicide Ideation (SSI) were randomly assigned in a 1:1 ratio to receive either sublingual buprenorphine (0.2 to 0.8 mg/day) or a matched placebo for 4 weeks, beginning 48 hours after a single open-label intravenous ketamine infusion (0.5 mg/kg over 40 minutes). The primary outcome was the change in SSI total score, assessed weekly from day 1 through day 31. RESULTS: From November 2020 to March 2025, 50 participants (68% female) received ketamine, of whom 45 completed at least 1 week of follow-on treatment. Both groups showed significant reductions in SSI total scores, with greater improvement in the buprenorphine group (mean change, -11.6, SD=5.8; N=23) than the placebo group (mean change, -6.3, SD=7; N=22) (Glass delta=0.76, 95% CI=0.11, 1.39). Mixed-effects modeling showed a significant time-by-treatment interaction (p<0.001). Depression scores did not differ significantly between groups. No serious treatment-related adverse events occurred. CONCLUSIONS: This randomized controlled trial provides the first evidence that a pharmacological intervention, buprenorphine, significantly sustains and enhances the antisuicidal effects of ketamine in MDD. These findings offer a potentially scalable and safe therapeutic option for a population at risk of suicide.
引用
- Tucciarone JM, Bandeira ID, Blasey C, et al. Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Psychiatry. 2026. PMID: 42151794. doi:10.1176/appi.ajp.20250840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。